Base de dados : LILACS
Pesquisa : D12.776.124.486.485.114.071 [Categoria DeCS]
Referências encontradas : 101 [refinar]
Mostrando: 1 .. 10   no formato [Longo]

página 1 de 11 ir para página                         

  1 / 101 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-623604
Autor: Sadigursky, Moysés; Von Kreuter, Betsy F; Santos-Buch, Charles A.
Título: Development of Chagasic autoimmune myocarditis associated with anti-idiotype reaction
Fonte: Mem. Inst. Oswaldo Cruz;83(supl.1):363-366, Nov. 1988. graf.
Idioma: en.
Conferência: Apresentado em: Annual Meeting on Basic Research in Chagas's disease, 15, Apresentado em: Meeting of the Brazilian Society of Protozoology4, Caxambu, 7-10 Nov. 1988.
Responsável: BR1.1 - BIREME


  2 / 101 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-623672
Autor: Colley, D. G; Parra, J. C; Montesano, M. A; Lima, M; Nascimento, E; Doughty, B. L; Goes, A; Gazzinelli, G.
Título: Immunoregulation in human Schistosomiasis by idiotypic interactions and lymphokine-mediated mechanisms
Fonte: Mem. Inst. Oswaldo Cruz;82(supl.4):105-109, 1987. graf, tab.
Idioma: en.
Conferência: Apresentado em: International Symposium on Schistosomiasis, Apresentado em: Reunião Nacional de Esquistossomose, 1, Rio de Janeiro, Oct. 25-30, 1987.
Projeto: UNDP; . World Bank; . WHO; . CNPq; . FINEP; . USA. Veterans Administration.
Resumo: Anti-idiotypic (anti-Id) T cells from schistosomiasis patients or former patients proliferate upon exposure to polyclonal or monoclonal anti-soluble egg antigen (SEA) antibodies. Chloroquine does not inhibit, the response, which is induced by F(ab')2 (but not soluble Fab) fragments of these antibodies. Purified T cells from former patients require macrophages or exogenous IL-1 to respond to anti-SEA Ids and can respond to matrix-bound Fab fragments in the presence of IL-1. These anti-Id T cells recognize the Ids directly. Chronic schistosomiasis patients immunoregulate the production of a non-IL-2 lymphokine that stimulates IL-2 receptor expression on resting T cells. This regulation is reversed upon chemotherapeutic cure.
Responsável: BR1.1 - BIREME


  3 / 101 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-831338
Autor: Lillo G., Macarena; Saavedra B., Giannina; Concha C., Francisca; Ávila A., Alejandra; Codner D., Ethel; Araya Q., Magdalena; Oyarzún A., Amaya; Pérez B., Francisco.
Título: Frecuencia de anticuerpos anti-transglutaminasa y antiendomisio en pacientes con diabetes tipo 1 / Association of type 1 diabetes mellitus with celiac disease
Fonte: Rev. chil. endocrinol. diabetes;9(1):15-18, ene. 2016. tab.
Idioma: es.
Projeto: Fondecyt.
Resumo: Background: Type 1 diabetes mellitus and celiac disease share common genetic and immunological aspects and celiac disease is more common among type 1 diabetic patients. Aim: To determine the frequency of anti endomysial and anti transglutaminase antibodies among patients with type 1 diabetes. Material and Methods: Anti endomysialantibodies determined by indirect immunofluorescence an anti transglutaminase antibodies determined by ELISA were measured in 410 serum samples of patients with type 1 diabetes. Results: Seventy one samples (17 percent) had positive anti transglutaminase antibodies. Among these, 17 had also positive anti endomysial antibodies. In 11 of these 17 patients, the presence of celiac disease was confirmed. Conclusions: Among patients with type 1 diabetes mellitus, the frequency of celiac disease is three times higher than in the general population.
Responsável: CL1.1 - Biblioteca Central


  4 / 101 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: lil-754751
Autor: Poitevin, Bernard.
Título: Las bases científicas de la homeopatía / The scientific basis of homeopathy
Fonte: Homeopatia Méx;83(693):31-40, nov.-dic. 2014.
Idioma: es.
Resumo: A través de un recorrido por los principios de la Homeopatía y la evolución de sus ideas es posible delimitar las líneas de investigación que podrían desarrollarse para responder las dudas e interrogantes que surgen de la aplicación de esta disciplina,situada entre las ciencias médicas, humanas, biológicas y físicas.A continuación se presenta el resumen de diversas investigaciones que han comprobado, por ejemplo, que los medicamentos homeopáticos sí actúan en células, modelos animales y seres humanos, aunque no se ha logrado explicarcómo; además, se pone de manifiesto que los criterios para evaluar no pueden ser idénticos a los que se emplean en la farmacología clásica, si bien existe cierta similitud.Se concluye que a pesar de que hay demasiados aspectos de la Homeopatía que siguen sin tener una explicación coherente en términos científicos clásicos, no deben rechazarse sin miramientos, sino estudiarse.

Through a tour of the principles of homeopathy and the evolution of his ideas is possible to delineate the lines of research that could be developed to answer the doubts and questions that arise from the application of this discipline, between the medical and social sciences, biological and physical.The summary of several studies that have found, for example is presented, that homeopathic medicines do act on cells, animal models and humans, but has not been able to explainhow; moreover, shows that the criteria for evaluating may not be identical to those used in classical pharmacology, while there is some similarity.We conclude that although there are too many aspects of homeopathy that still lack a coherent explanation in classical scientific terms, should not be rejected without consideration, but studied.
Responsável: BR926.1 - Biblioteca Artur de Almeida Rezende Filho


  5 / 101 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Saúde Pública
Silva, Luciana Rodrigues
Assis, Ana Marlúcia Oliveira
Texto completo
Id: lil-736438
Autor: Conceição-Machado, Maria Ester Pereira da; Santana, Mônica Leila Portela; Silva, Rita de Cássia Ribeiro; Silva, Luciana Rodrigues; Pinto, Elizabete Jesus; Couto, Ricardo David; Moraes, Lia Terezinha Lana Pimenta; Assis, Ana Marlúcia Oliveira.
Título: Triagem sorológica para doença celíaca em adolescentes / Serologic screening of celiac disease in adolescents
Fonte: Rev. bras. epidemiol;18(1):149-156, Jan-Mar/2015. graf.
Idioma: pt.
Projeto: Fundação de Amparo à Pesquisa do Estado da Bahia.
Resumo: OBJETIVO: Este estudo objetivou identificar a soroprevalência da doença celíaca em adolescentes de escolas públicas da cidade de Salvador, Bahia. MÉTODO: Trata-se de um estudo transversal com amostra probabilística de 1.213 adolescentes de 11 a 17 anos, de ambos os sexos. O índice de massa corporal foi utilizado para o diagnóstico do estado nutricional, adotando-se os percentis segundo idade e sexo, propostos pela World Health Organization. O anticorpo anti-transglutaminase humana da classe imunoglobulina A (anti-tTG-IgA) foi adotado como teste sorológico para triagem da doença celíaca e foi determinado pela técnica do ensaio imunoabsorvente ligado à enzima (ELISA). Foi realizada análise descritiva, utilizando-se a proporção e a média (desvio padrão). RESULTADOS: O sexo feminino predominou entre os adolescentes, e a maioria encontrava-se com adequado estado nutricional. O anticorpo anti-tTG-IgA foi positivo em 6/1.213 (0,49%) adolescentes. CONCLUSÃO: A soroprevalência de doença celíaca entre os adolescentes estudados foi 0,49%. Novas investigações são necessárias para confirmar a prevalência de doença celíaca nessa faixa etária. .

OBJECTIVE: This study aimed to identify the seroprevalence of celiac disease in adolescents from public schools in the city of Salvador, Bahia. METHODS: This was a cross-sectional study with probabilistic sample of 1,213 adolescents, aged 11 to 17 years old, of both genders. The body mass index was used to determine the participants' nutritional status based on the percentiles for age and gender recommended by the World Health Organization. Measurement of the anti-human transglutaminase immunoglobulin A (anti-tTG-IgA) antibody was established as the specific screening test for celiac disease, which involved an enzyme-linked immunosorbent assay (ELISA). Descriptive analysis was performed using proportions and means (standard deviation). RESULTS: The female gender prevailed in the sample, and most of the participants had normal weights. The anti-tTG-IgA antibody was positive in 6/1,213 (0.49%) adolescents. CONCLUSION: The seroprevalence of celiac disease was 0.49% in the investigated adolescents. Further studies are necessary to establish the prevalence of celiac disease in this age range. .
Responsável: BR1.1 - BIREME


  6 / 101 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: lil-734856
Autor: Rodríguez, Graciela Rita; Zazzetti, Federico; da Representaçao, Silvia Raquel; Lencina, María Verónica; Barreira, Juan Carlos; Álvarez, Karina Elizabeth.
Título: Frecuencia de anticuerpos para diagnóstico de enfermedad celíaca en pacientes con enfermedades del tejido conectivo y artropatías inflamatorias / Serum anti endomysial and anti transglutaminase antibodies in patients with connective tissue diseases
Fonte: Rev. méd. Chile;142(12):1510-1516, dic. 2014. ilus, tab.
Idioma: es.
Resumo: Background: The detection of anti-transglutaminase IgA (tTG) and anti-endomysial (EMA) is used for screening of celiac disease (CD) with a sensitivity and specificity of 90 and 99% respectively. There is an association between CD and connective tissue diseases (CTD). Aim: To report the frequency of IgA tTG and EMA in patients with a definite diagnosis of CTD and inflammatory arthropathies (IA). Material and Methods: One hundred forty nine patients, aged 19 to 86 years (133 females) with CTD and IA were studied. tTG were determined by ELISA and EMA by indirect immunofluorescence. Results: Eight participants had at least one positive antibody (5.4%, confidence intervals (CI) = 1.8-9), six had both (4.0% CI = 0.9-7.2) and two had only tTG positive. An intestinal biopsy was performed in four of these participants, finding a marked villous atrophy in three and partial atrophy in one. Conclusions: Five percent of this group of patients with CTD or IA had positive antibodies for CD.
Responsável: CL1.1 - Biblioteca Central


  7 / 101 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-734416
Autor: Máspero, Jorge; Cabrera, Hugo; Ardusso, Ledit; De Gennaro, Mónica; Fernández Bussy, Ramón; Galimany, José; Galimberti, Daniel; Label, Marcelo; La Forgia, Marta; Medina, Iris; Neffen, Hugo; Troielli, Patricia.
Título: Guía Argentina de urticaria y angioedema
Fonte: Medicina (B.Aires);74(supl.1):1-53, ago. 2014. ilus, tab.
Idioma: es.
Resumo: Se actualiza el diagnóstico de la urticaria crónica (UC) y los conceptos, definiciones y sugerencias basados en la evidencia para su tratamiento. La urticaria ocurre en al menos 20% de la población en algún momento de la vida. Su etiología difiere en la forma aguda (menos de 6 semanas), y en la crónica. No es posible pronosticar si las formas agudas evolucionarán a UC, ya que todas son agudas al comienzo. La UC ocurre como espontánea (UCE) o inducible (UCI). El diagnóstico es sencillo, pero incluye un minucioso estudio para descartar diagnósticos diferenciales; para UCI son útiles las pruebas de provocación en la caracterización y manejo. Los estudios complementarios se deben limitar y orientar según sospecha clínica. El tratamiento se divide en tres enfoques: evitación, eliminación o tratamiento del estímulo desencadenante o de la causa, y tratamiento farmacológico. Recientemente éste se modificó, con empleo de antihistamínicos de segunda generación como primera línea y aumento de dosis de antihistamínicos H1 no sedantes, hasta 4 veces, como segunda línea. Los antihistamínicos son fundamentales para tratar la UC; sin embargo, un 40% de los pacientes no logra un buen control pese al aumento de dosis y requiere otro medicamento adicional. La evidencia más reciente considera que un grupo de fármacos puede utilizarse como tercera línea en estos casos, para mejorar la calidad de vida y limitar la toxicidad por el uso frecuente o crónico de esteroides sistémicos. Se recomiendan para esta tercera línea solo 3 fármacos: omalizumab, ciclosporina A o antileucotrienos.

This interdisciplinary paper summarizes the news in the diagnosis and treatment of chronic urticaria (CU), and provides concepts, definitions and evidence-based suggestions for its management. Urticaria occurs in at least 20% of the population at some point in their lives. Acute urticaria (less than 6 weeks' duration), differs from CU in its etiology, but the onset of this disease is always acute. CU may occur as spontaneous (SCU) or induced (ICU). The diagnosis is simple, although a careful evaluation is necessary for differential diagnosis. ICU´s diagnosis is mainly clinical, even if provocation tests can be useful. Supplementary studies should be limited and based on the clinical suspicion. Treatment may be divided into three approaches: avoidance, elimination or treatment of the cause, and pharmacological treatment. Recently treatment has been modified with the use of second-generation antihistamines as first-line and increased doses of nonsedating H1 antihistamines, up to 4 times, as second line. Antihistamines are essential to treat CU; however, 40% of patients do not achieve good control despite increased doses and require additional treatment. The most recent evidence indicates a group of drugs to be used as third line in these cases, to improve quality of life and to limit toxicity from frequent or chronic use of systemic steroids. Only 3 drugs are recommended as third line: omalizumab, cyclosporin A or anti-leukotrienes.
Responsável: AR1.2 - Instituto de Investigaciónes Epidemiológicas


  8 / 101 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: lil-724702
Autor: León de González, Graciela; Cerdas Quesada, César.
Título: Grupo Cooperativo Iberoamericano de Medicina Transfusional. Programa Consulta al Experto. La prueba de antiglobulina directa: el dilema entre lo clínicamente significativo y lo no significativo / Ibero-American Cooperative Group on Transfusion Medicine. Consulting the Expert. The direct antiglobulin test: the dilemma between clinically significant and insignificant
Fonte: Rev. argent. transfus;39(1/2):55-61, 2013. ilus, tab.
Idioma: es.
Responsável: AR1.1 - Biblioteca Rafael Herrera Vegas


  9 / 101 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-700468
Autor: Díez, Libia Susana; Tamayo, Liliana María; Cardona, Ricardo.
Título: Omalizumab: opción terapéutica para la urticaria crónica espontánea de difícil control con vasculitis asociada, reporte de tres casos / Omalizumab: therapeutic option in chronic spontaneous urticaria difficult to control with associated vasculitis, report of three cases
Fonte: Biomédica (Bogotá);33(4):503-512, Dec. 2013. ilus, tab.
Idioma: es.
Resumo: Introducción. Aproximadamente el 50 % de los casos de urticaria crónica no mejoran adecuadamente con las dosis convencionales de antihistamínicos, por lo cual se han planteado múltiples opciones terapéuticas, entre las cuales el omalizumab es una herramienta novedosa que ahora cuenta con evidencia de alta calidad que soporta su uso en los casos difíciles, que mejora rápidamente el índice sintomático y el uso de medicamentos, y cuenta con un buen perfil de seguridad. Objetivo. Presentar tres casos de mujeres adultas con urticaria crónica espontánea de más de ocho años de evolución, que no mejoraron con el tratamiento con altas dosis de antihistamínicos, asociados a antileucotrienos e inmunomoduladores y en quienes se combinaban varios mecanismos fisiopatológicos: urticaria crónica espontánea con componente de autoinmunidad, componente de presión y urticaria vasculítica. Materiales y métodos. Se reportan los casos con sus respectivas evaluaciones clínicas y de laboratorio, los medicamentos usados y la respuesta después del inicio de omalizumab y se hace una revisión de la literatura científica sobre uso de este medicamento en la urticaria crónica. Resultados. En los tres casos presentados se obtuvo una mejoría completa de los síntomas tras el inicio del omalizumab. Conclusión. El omalizumab es una opción terapéutica exitosa en casos de urticaria crónica de difícil control con vasculitis asociada, cuando se han agotado las opciones propuestas por las guías internacionales.

Introduction: Approximately 50% of chronic urticaria cases do not respond adequately to conventional doses of antihistamines, so a number of other therapeutic options have been suggested. Among these, omalizumab is an innovative tool, which now has high-quality evidence that supports its use in difficult cases, rapidly improving the symptom index and the use of medications with a good safety profile. Objective: To report three cases of adult women with spontaneous chronic urticaria with an evolution of more than eight years, which did not improve with high doses of antihistamines and leukotriene receptor blockers, associated with immunomodulatory therapy in which several etiologic mechanisms were combined: chronic spontaneous urticaria with autoimmune and pressure components, and vasculitis. Materials and methods: We report the cases with their clinical and laboratory evaluations, used medication, the response after the start of omalizumab and we performed a review of the literature on the use of this drug in chronic urticaria. Results: In all the presented cases, we obtained complete improvement of symptoms after starting omalizumab. Conclusion: Omalizumab is a successful treatment option in cases of difficult to control chronic urticaria with associated vasculitis in which the options proposed by international guidelines have been exhausted.
Responsável: CO332 - Facultad de Medicina


  10 / 101 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: lil-699689
Autor: Uribe S.M, Reinaldo; Suárez H, Felipe; Sandoval R, Patricio; Mellado T, Patricio.
Título: Síndrome anti-GQ1b: Descripción de cuatro pacientes y revisión de la literatura / Anti-GQ1b syndrome: Report of four cases
Fonte: Rev. méd. Chile;141(9):1211-1215, set. 2013. tab.
Idioma: es.
Resumo: Anti-GQ1b syndrome includes Miller Fisher Syndrome (MFS), Guillain Barré Syndrome (GBS), Bickerstaff`s brain stem encephalitis (BBE) and Acute Ophtamoplegia (AO). We report four patients aged 16 to 76 years, with anti-GQ1b syndrome. All presented with MFS, one of them evolved to GBS pharyngeal-cervical-brachial variant and other to GBS with BBE. All had a previous history of diarrhea or upper respiratory tract infection. All had positive anti-GQ1b serum antibodies. Both brain magnetic resonance imaging and cerebrospinal fluid analysis were normal. Electrophysiology studies were compatible with a demyelinating disease. Two patients needed airway protection with an orotracheal tube and developed dysautonomia. All four patients were treated with immunomodulation. On the sixth month follow-up, patients had only minimal alterations in the neurological examination.
Responsável: CL1.1 - Biblioteca Central



página 1 de 11 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde